Calyx expresses immense thanks to all our business associates, financial institutions, our suppliers and last but not the least to all Calyxians and the Calyx family.
The story unfolds ….

Former US President Bill Clinton joined by the UN Special Envoy on Malaria announced agreements with six companies including Calyx, that lower the price of a leading artemisinin-based combination therapy (ACT) for malaria by 30 percent and reduce the price volatility of artemisinin, the key raw material for this and other ACTs, by 70 percent. With this agreement Calyx extends its product range into Malaria.

“Nearly every life lost to malaria could have been saved with access to effective medicines,” President Clinton said. “My Foundation has helped organize markets for HIV/AIDS drugs, and I am proud that we have been able to extend this model to malaria. Today’s announcement is an important step forward in global efforts to increase access to affordable and effective malaria treatment, and I applaud the commitments of these companies to lower volatility in this market and offer low and sustainable prices that will save more lives.”

Daniel Vasella, Chairman of Novartis, said the problems and challenges are of such magnitude that nobody can solve them alone, not the Government, not the private industries and not the NGOs, only a collaboration between all of these partners can help to better the condition in the developing nations. Mr. Vasella encouraged his traditional competitors, the Generic manufacturers to work together to be successful in this social cause. As an expression of his respect for his Indian colleagues present at the event he finished with a quote of Mahatma Gandhi, “ We have to be the change we want to see in the world”.

Role Of Calyx
Calyx has a 29-year history of building up successful partnerships and this agreement with Clinton Foundation is another major step in honouring social responsibility. We have taken an important step forward to supply artemisinin derivatives at a price which will make the effective malaria treatment affordable and accessible to various countries in Africa, Asia, Latin America and the Caribbean that make up the Clinton HIV/AIDS Initiative (CHAI) purchasing consortium.

Left to Right : Raymond Chambers – UN Special Envoy on Malaria, Smitesh Shah – CMD Calyx, Bill Clinton and Daniel Vasella – CEO Novartis

Link to the full video of the event at Mr. Clinton’s Office
http://www.kaisernetwork.org/health_cast/player.cfm?id=4347

---

Read below the speech of Mr. Smitesh Shah, Chairman & CEO of Calyx at the launch ceremony on 17th July, 2008 at Mr. Clinton’s Office in New York

President Sir, although we are a business at Calyx, we have another objective, one that is shared with The Clinton Foundation and that is to serve as many patients as possible.

There is a quote that sits on the wall of our office, “No exercise is better for the human heart than reaching down and lifting another arm.” We try to live this through our business. This is evidenced by our past work that we have been associated with The Global Fund for Tuberculosis. We have been an active supplier of APIs to all the formulations for the last 15 years and now we intend to work on Malaria.

Calyx is a producer of APIs and restricts itself of being an API producer. Mr. Daniel Vasella, we classify we would not enter into competition for finished dosages.

Calyx has a world class R&D team, it is committed to deploy it resources of R&D also for the developing nations. Calyx works with large multinational companies all across the globe. We offer Contract Research and Manufacturing services. We continue to work on innovation but we offer only services as a part of our global initiative.

In sync with India Inc. Calyx is annually growing at 40% and we continue to believe that with malaria and other drugs our growth will continue at the rate of 40%.

We are proud to be working with The Clinton Foundation. This is our first partnership with a non governmental organization and one thing that strikes me about our work to date is the Clinton Foundation’s ability to understand how we as business people think.

My congratulations to Mr. Inder Singh and his team for having done a wonderful job, being with us, holding our hands, understanding the pharmacopoeia difficulties and solving them. As a buyer of artemisinin, I can tell you first hand about the volatility of its prices and how this has created disincentives to enter the business. The Clinton Foundation’s work demonstrated by the announcement of these agreements focuses correctly on reducing the financial risk associated with this volatility.

Commercial Scale
  Antitubercular
  Pyrazinamide
  Isoniazid
  Rifampicin
  Antimalarial
  Artesunate
  Arteether
  Artemether
  Dihydroartemisinin
  Lumefantrine
  Macrolides
  Azithromycin
  Clarithromycin
  Erythromycin base
  Erythromycin estolate
  Erythromycin ethylsuccinate
  Erythromycin oxime  (intermediate)
  Erythromycin phosphate
  Erythromycin propionate
  Erythromycin stearate
  Antihypertensive
  Lisinopril dihydrate
  Losartan potassium
  Irbesartan
  Valsartan
  Antiepileptic
  Sodium valproate
  Valproic acid
  Divalproex sodium
  Antiosteoporotic
  Alendronate sodium
  Zoledronic acid
  Sedative, Hypnotic
  Zopiclone
  Antidepressant
  Venlafaxine hydrochloride
  Antihistaminic   
  Cetirizine dihydrochloride
  Meclizine dihydrochloride
  Hydroxyzine dihydrochloride
  Antithrombotic
  Clopidogrel bisulphate  

  Pilot Plant Scale
  Carvedilol
  Pioglitazone hydrochloride
  Rosiglitazone maleate
  Eszopiclone
  
  R & D Scale
  Candesartan
  Eprosartan
  Olmesartan
  Telmisartan

  Development
  Benazepril hydrochloride
  Desvenlafaxine
  Levocetirizine
  Ramipril
  Rifabutin
  Rifapentine
  Risedronic acid

     Product under patent  offered  only
      for exempted research, clinical and
      development  purposes. Only  non-
      infringing   products   and  processes
      are offered, subject to patent status
      verification by client.

Services

Custom Synthesis

Contract Research

Contract Manufacturing

FTE and FFS

APIs and Intermediates

Building Blocks

Analytical Services

Our partnership with The Foundation enables Calyx as business to do work and to do even better as I mentioned earlier “serve as many patients as possible”.

Nothing happens without the hand of God...HIS guidance, HIS grace and a torrent of HIS blessings.
Clinton Foundation has SET THE SAILS... THE LORD WILL BLOW THE WIND.

India Operations: Mr. Jitendra Shah : +91-22-28031520       jitendra_shah@calyxindia.com
Europe Operations: Mr. Prashant Ogale : +91-251-2438310 ext: 585 prashant_ogale@calyxindia.com
US Operations: Mr. Bharat K. Shah : +91-860-6910186         bharat.k.shah@calyxusa.com
Japan Operations: Dr. Sanjeev Gupte : +91-251-2438310     sanjeev_gupte@calyxindia.com

To unsubscribe from this Newsletter send blank email to pharmanews@calyxindia.com